Title : CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.

Pub. Date : 2021 Mar

PMID : 33429148






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Exploring mechanisms, we found that inhibition of CDK12 attenuated PI3K/AKT signal, which usually serves as an oncogenic driver and is reactivated when HER2-positive breast cancers develop resistance to lapatinib. Lapatinib AKT serine/threonine kinase 1 Homo sapiens
2 Combining CDK12 inhibition exerted additional suppression on p-AKT activation induced by anti-HER2 TKIs lapatinib treatment. Lapatinib AKT serine/threonine kinase 1 Homo sapiens